Michael S. Benn is a Partner in Wachtell, Lipton, Rosen & Katz’s Restructuring and Finance Department. He represents borrowers with respect to all types of financing for mergers and acquisitions, spin-offs and other significant transactions across a wide variety of industries.

Representative matters include: 3M’s $5.3 billion combination of its Food Safety business with Neogen Corporation in a Reverse Morris Trust transaction,  Encompass Health Corporation’s spin-off of its home health and hospice business, Pfizer’s $48 billion combination of Upjohn with Mylan, United Technologies’ separation of its Otis and Carrier businesses (including the issuance by Otis and Carrier of $5.3 billion and $9.25 billion, respectively, of senior unsecured notes), AbbVie’s $21 billion acquisition of Pharmacyclics,  Johnson Controls’ $16.3 billion combination with Tyco International plc and spinoff of Adient plc, Abbott Laboratories’ $25 billion acquisition of St. Jude Medical and $2.8 billion term loan to finance its acquisition of Alere Inc., Walgreens Boots Alliance’s acquisition of Alliance Boots, Danone S.A.’s acquisition of The WhiteWave Foods Company, Hubbell Incorporated’s acquisition of Meter Readings Holding Group, LLC, Searchlight Capital’s $2 billion acquisition of Mitel Networks, ServiceMaster’s spin-off of frontdoor, inc. and PVH’s $3 billion acquisition of Warnaco.

Mike also frequently represents sellers in financing matters relating to major M&A transactions, including Allergan in its $83 billion acquisition by AbbVie, Celgene in its $98 billion sale to Bristol-Myers Squibb, Thomson Reuters in its strategic partnership with Blackstone for Thomson Reuters Financial and Risk (F&R) business valued at $20 billion, TEGNA in its $8.6 billion all-cash acquisition by Standard General, SUPERVALU in its $2.9 billion sale to United Natural Foods and Cantel Medical Corporation in its $4.6 billion sale to STERIS.

In the distressed and restructuring space, among other projects, Mike has represented an Ad Hoc Group of Noteholders (including affiliates of Capital Group, BlackRock, CI Investments, Manulife, Mesirow and CastleKnight) in connection with the contested Chapter 11 cases of Altera Infrastructure L.P., Capital Group, Barings LLC and Aegon in connection with the contested Chapter 11 case of Hertz Global Holdings, Bausch Health as the stalking horse bidder in Synergy Pharmaceuticals’ §363 sale of substantially all its assets, Education Management in connection with its $1.5 billion out-of-court recapitalization, Credit Suisse, as first-lien administrative and collateral agent, in connection with the contested $1.1 billion §363 sale in bankruptcy of certain assets of Boston Generating to Constellation Energy Group, and ad hoc lender groups in connection with various Chapter 11 cases, including the restructuring of Rotech Healthcare Inc. and Riviera Holdings.

Mike received a B.A. summa cum laude and with distinction in all subjects from Cornell University in 2002, where he was a member of Phi Beta Kappa and a Merrill Presidential Scholar and completed a J.D. from the University of Pennsylvania Law School in 2007, where he was a member of the Order of the Coif and an associate editor of the University of Pennsylvania Law Review. He also received an M.A. in theatre studies from Brown University in 2004.

Mike has been named to the “500 Leading Dealmakers in America” by Lawdragon, a “Notable Practitioner” by the ILFR1000 and a “Rising Star” in the New York metropolitan area by SuperLawyers and is a member of the Board of Trustees of The Leffell School and Temple Israel Center of White Plains.